Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Merck and : NOXXON announces its participation in two french investor conferences in October 2017

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/02/2017 | 10:18am CEST

Release date- 29092017 - Berlin, Germany - NOXXON Pharma N.V. (EuroNext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced that it would participate in two conferences focused on institutional investors in October in Paris.

NOXXON will present at the French Financial Analysts Society / Societe Francaise des Analystes Financiers (SFAF) on October 3, 2017 at 10:00am at 135 boulevard Haussmann, 75008 Paris in the 'Salle Hausmann'.

NOXXON will also participate in the CF&B Large & Midcap Event which will take place on the 4th and 5th of October 2017 at the Palais Brongiart, 28 Place de la Bourse, 75002 Paris. NOXXON pharma will be available for meetings with institutional investors.

Contact:

Tel: +49 (0) 30 726 247 0

Email: amangasarian@noxxon.com

About NOXXON

NOXXON Pharma N.V. is a clinical-stage biopharmaceutical company focused on cancer treatment. NOXXON's goal is to significantly enhance the effectiveness of cancer treatments including immunooncology approaches (such as immune checkpoint inhibitors) and current standards of care (such as chemotherapy and radiotherapy).

NOXXON's Spiegelmer platform has generated a proprietary pipeline of clinical-stage product candidates including its lead cancer drug candidate NOX-A12 (olaptesed pegol), which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD (NYSE: MRK) to study NOX-A12 combined with Merck & Co.'s anti-PD-1 checkpoint-inhibiting antibody Keytruda (pembrolizumab) in pancreatic and colorectal cancer. The clinical trial testing NOX-A12 as monotherapy and in combination with Keytruda is being conducted at one of the leading centers for cancer research and treatment, the National Center for Tumor Diseases in Heidelberg, Germany. NOXXON is supported by a strong group of leading international investors, including TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, DEWB, NGN and Seventure. NOXXON has its statutory seat in Amsterdam, the Netherlands and its office in Berlin, Germany.

Disclaimer

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.

(c) 2017 Electronic News Publishing -, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
MERCK AND COMPANY -0.18% 70.65 Delayed Quote.25.79%
NOXXON PHARMA NV 0.79% 2.56 Real-time Quote.-65.04%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
09/25DAIICHI SANKYO : Announces Clinical Research Collaboration to Evaluate DS-8201 i..
AQ
09/25Gilead targets Medicaid with launch of HCV generics
AQ
09/21MERCK FOLLOWS OPDIVOS SUIT, PRICES K : report
AQ
09/20MERCK : Receives Positive CHMP Opinion for DELSTRIGO™ (doravirine/lamivudi..
BU
09/20MERCK AND : Publishes Corporate Responsibility Report
PR
09/19ASTELLAS PHARMA : Announces Launch of Dafclir Tablets for the Treatment of Infec..
AQ
09/18DOW MOVERS : Dis, aapl
AQ
09/14MERCK AND : FDA Grants Priority Review to Merck's Application for KEYTRUDA Monot..
AQ
09/14MERCK AND COMPANY : Ex-dividend day for
FA
09/13Roche steps up efficiency drive to take sting out of biosimilars
RE
More news
News from SeekingAlpha
09/25MERCK : $70+ A Share Might Not Be That Expensive 
09/25Pfizer facing difficult path to ramp up biosimilar business 
09/25ARVINAS IPO : 40% Is Cash, But Research Is At An Early Stage 
09/25Down With The Dow 
09/24Express Scripts taking credit for Gilead's planned launch of generic HCV meds 
Financials ($)
Sales 2018 42 371 M
EBIT 2018 13 742 M
Net income 2018 7 016 M
Debt 2018 14 978 M
Yield 2018 2,75%
P/E ratio 2018 27,37
P/E ratio 2019 18,45
EV / Sales 2018 4,79x
EV / Sales 2019 4,54x
Capitalization 188 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 73,0 $
Spread / Average Target 3,4%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY25.79%187 895
JOHNSON & JOHNSON2.26%376 847
PFIZER20.90%257 522
NOVARTIS-0.63%217 697
ROCHE HOLDING LTD.-5.48%209 212
AMGEN17.94%134 121